Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US FDA has approved Lannett Company's Abbreviated New Drug Application (ANDA) for Diethylpropion HCl Extended Release Tablets, 75 mg.
Subscribe to our email newsletter
Diethylpropion HCl, like many anti-obesity drugs, is primarily sold to bariatric clinics, the company said.
Lannett president and CEO Arthur P Bedrosian said the approval would add to their line of anti-obesity medications.
"Our pipeline remains deep, with a number of ANDAs currently pending at the FDA, several of which we expect to be approved over the next couple of quarters," Bedrosian added.